160 related articles for article (PubMed ID: 24957115)
1. Successful treatment of a bullous urticaria with omalizumab.
Ozturk AB; Kocaturk E; Ozturk E
Allergol Int; 2014 Sep; 63(3):495-7. PubMed ID: 24957115
[No Abstract] [Full Text] [Related]
2. Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.
Rodríguez-Trabado A; Fernández Pereira LM; Romero-Chala S; García-Trujillo JA; Cámara Hijón C
Allergol Immunopathol (Madr); 2012; 40(6):390-2. PubMed ID: 22178123
[No Abstract] [Full Text] [Related]
3. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
4. An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.
Uysal P; Eller E; Mortz CG; Bindslev-Jensen C
J Allergy Clin Immunol; 2014 Mar; 133(3):914-5.e2. PubMed ID: 24360324
[No Abstract] [Full Text] [Related]
5. Long-term treatment of severe recalcitrant atopic dermatitis with omalizumab, an anti-immuno-globulin E.
Quist SR; Ambach A; Göppner D; Quist J; Franke I; Bonnekoh B; Gollnick HP
Acta Derm Venereol; 2013 Mar; 93(2):206-8. PubMed ID: 23042516
[No Abstract] [Full Text] [Related]
6. Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.
Wu KCP; Jabbar-Lopez ZK
J Invest Dermatol; 2015 Jan; 135(1):13-15. PubMed ID: 25501377
[TBL] [Abstract][Full Text] [Related]
7. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema.
Lang DM
Ann Allergy Asthma Immunol; 2014 Apr; 112(4):276-9. PubMed ID: 24589165
[No Abstract] [Full Text] [Related]
8. Ligelizumab for Chronic Spontaneous Urticaria.
Maurer M; Giménez-Arnau AM; Sussman G; Metz M; Baker DR; Bauer A; Bernstein JA; Brehler R; Chu CY; Chung WH; Danilycheva I; Grattan C; Hébert J; Katelaris C; Makris M; Meshkova R; Savic S; Sinclair R; Sitz K; Staubach P; Wedi B; Löffler J; Barve A; Kobayashi K; Hua E; Severin T; Janocha R
N Engl J Med; 2019 Oct; 381(14):1321-1332. PubMed ID: 31577874
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in the treatment of chronic urticaria.
Francés L; Leiva-Salinas M; Silvestre JF
Actas Dermosifiliogr; 2014; 105(1):45-52. PubMed ID: 23938072
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
11. Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light.
Duchini G; Bäumler W; Bircher AJ; Scherer K
Photodermatol Photoimmunol Photomed; 2011 Dec; 27(6):336-7. PubMed ID: 22092741
[TBL] [Abstract][Full Text] [Related]
12. Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy.
Cavelti-Weder C; Muggli B; Keller C; Babians-Brunner A; Biason-Lauber A; Donath MY; Schmid-Grendelmeier P
Diabetes Care; 2012 Jun; 35(6):e41. PubMed ID: 22619293
[No Abstract] [Full Text] [Related]
13. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Benralizumab in a Patient Who Did Not Respond to Omalizumab.
Bernal-Rubio L; de-la-Hoz Caballer B; Almonacid-Sánchez C; González-de-Olano D
J Investig Allergol Clin Immunol; 2020; 30(5):378-379. PubMed ID: 32376515
[No Abstract] [Full Text] [Related]
15. Expanding the spectrum: chronic urticaria and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
Lundberg C; Martinez B; Banks TA
Ann Allergy Asthma Immunol; 2015 Apr; 114(4):353-4. PubMed ID: 25707324
[No Abstract] [Full Text] [Related]
16. Omalizumab. An option in vernal keratoconjunctivitis?
Sánchez J; Cardona R
Allergol Immunopathol (Madr); 2012; 40(5):319-20. PubMed ID: 21975146
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.
Maurer M; Altrichter S; Bieber T; Biedermann T; Bräutigam M; Seyfried S; Brehler R; Grabbe J; Hunzelmann N; Jakob T; Jung A; Kleine-Tebbe J; Mempel M; Meurer M; Reich K; Ruëff F; Schäkel K; Sengupta K; Sieder C; Simon JC; Wedi B; Zuberbier T; Mahler V; Staubach P
J Allergy Clin Immunol; 2011 Jul; 128(1):202-209.e5. PubMed ID: 21636116
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab is effective in nonautoimmune urticaria.
Ferrer M; Gamboa P; Sanz ML; Goikoetxea MJ; Cabrera-Freitag P; Javaloyes G; Berroa F; Kaplan AP
J Allergy Clin Immunol; 2011 May; 127(5):1300-2. PubMed ID: 21315432
[No Abstract] [Full Text] [Related]
19. Omalizumab for the treatment of chronic urticaria.
Zuberbier T; Maurer M
Expert Rev Clin Immunol; 2015 Feb; 11(2):171-80. PubMed ID: 25566680
[TBL] [Abstract][Full Text] [Related]
20. Biologic agents and the therapy of chronic spontaneous urticaria.
Kaplan AP; Popov TA
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):347-53. PubMed ID: 24936849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
